$1250 | Single User
$1800 | Site License
$2500 | Global License

Activated PI3K Delta Syndrome (APDS) Therapeutic Market: Opportunities Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)
[Lowest Price Guaranteed: $1,250]

Published by Gervano R A: 01 Jun 2017 | 270535 | In Stock
Related Topics: Clinical Trials , Drug

Introduction

GervanoRA's Market Estimation report "Activated PI3K Delta Syndrome (APDS): Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2019-2025)" analyzed the current and upcoming opportunities in the Activated PI3K Delta Syndrome (APDS) area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Activated PI3K Delta Syndrome (APDS) industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analysis and Clinical Trials summary to provide in depth insights about the market dynamics and ongoing R&D in the Activated PI3K Delta Syndrome (APDS) area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Activated PI3K Delta Syndrome (APDS) Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed and pipeline drugs to provide a brief understanding about the market opportunities in the Activated PI3K Delta Syndrome (APDS) competitive environment. We have also prognosticated the Activated PI3K Delta Syndrome (APDS) market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

Epidemiology and Epidemiology forecast 2019 - 2025

Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)

Estimated Pipeline Drug Approval Timelines

Clinical Trials Summary

Current and Future Competitive Landscape

Key Company Profiles with SWOT Analysis

Emerging Company Profiles with Opportunity Assessments

Pipeline Drug Descriptions along with Development milestones (Past and Future)

University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.

Table of Contents
for Activated PI3K Delta Syndrome (APDS) Therapeutic Market: Opportunities Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)

  • TABLE OF CONTENTS

    1. INTRODUCTION

    1.1. REPORT DESCRIPTION

    1.2. METHODOLOGY

    1.3. UPCOMING AND OTHER AVAILABLE REPORTS

    1.4. ABOUT US: GERVANORA DATA SERVICES

    2. EXECUTIVE SUMMARY

    2.1. MARKET SNAPSHOT, 2019-2025

    2.2. KEY EVENTS IN ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET, 2015-2030

    2.3. PRODUCT LIFE CYCLE MANAGEMENT (LCM) STRATEGIES

    2.4. KEY MAJOR FINDINGS

    2.4.1. DRIVERS

    2.4.2. RESTRAINTS

    2.4.1. UNMET NEEDS AND OPPORTUNITIES

    3. DISEASE OVERVIEW

    3.1. DISEASE DEFINITION & SYMPTOMS

    3.1.1. CLINICAL MANIFESTATIONS

    3.1.2. PATHOGENESIS

    3.2. DISEASE CAUSE AND CLASSIFICATION

    3.3. DISEASE DIAGNOSIS

    3.4. TREATMENT ALGORITHM AND GUIDELINES

    3.5. EPIDEMIOLOGY AND DISEASE BURDEN

    3.6. EPIDEMIOLOGY FORECAST

    3.6.1. FORECAST METHODOLOGY AND ASSUMPTION

    3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

    4. MARKET OVERVIEW

    4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT

    4.2. PRICING AND REIMBURSEMENT

    4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)

    4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010

    4.5. NEW DRUG APPROVALS (EMA) SINCE 2010

    4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)

    5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE

    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT

    5.1.1. PRE-REGISTRATION (FILED) MOLECULES

    5.1.2. PHASE 3 MOLECULES

    5.1.3. PHASE 2 MOLECULES

    5.1.4. PHASE 1 MOLECULES

    5.1.5. PRECLINICAL MOLECULES

    5.1.6. EARLY R&D MOLECULES

    5.1.7. INACTIVE AND TERMINATED MOLECULES

    5.2. PIPELINE ANALYSIS BY GEOGRAPHY

    5.2.1. UNMET NEEDS AND OPPORTUNITIES

    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

    5.3.1. UNMET NEEDS AND OPPORTUNITIES

    5.4. PIPELINE ANALYSIS BY DRUG CLASS

    5.4.1. UNMET NEEDS AND OPPORTUNITIES

    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION

    5.5.1. UNMET NEEDS AND OPPORTUNITIES

    5.6 PIPELINE ANALYSIS BY UNIVERSITIES AND INSTITUTES

    5.7. ESTIMATED APPROVAL TIMELINES

    5.7.1. METHODOLOGY

    5.7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

    6. ACTIVATED PI3K DELTA SYNDROME (APDS) CLINICAL TRIALS SUMMARY

    6.1. ACTIVATED PI3K DELTA SYNDROME (APDS) PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS

    6.1.1. KEY PHASE 3 RESULTS

    6.1.2. KEY PHASE 2 RESULTS

    6.2. ONGOING CLINICAL TRIALS SUMMARY

    6.2.1. KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY

    6.2.2. KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY

    6.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY

    6.3 PLANNED CLINICAL TRIALS SUMMARY

    6.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY

    6.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY

    6.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY

    6.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY

    7. ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY DRUG CLASS

    8. ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY ROUTE OF ADMINISTRATION

    9. ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY GEOGRAPHY

    9.1. UNITED STATES

    9.1.1. MARKET TRENDS AND GROWTH FACTORS

    9.1.2. UNMET NEEDS AND OPPORTUNITIES

    9.1.3. US ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.2. UNITED KINGDOM

    9.2.1. MARKET TRENDS AND GROWTH FACTORS

    9.2.2. UNMET NEEDS AND OPPORTUNITIES

    9.2.3. UK ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.3. GERMANY

    9.3.1. MARKET TRENDS AND GROWTH FACTORS

    9.3.2. GERMANY ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.4. FRANCE

    9.4.1. MARKET TRENDS AND GROWTH FACTORS

    9.4.2. UNMET NEEDS AND OPPORTUNITIES

    9.4.3. FRANCE ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.5. ITALY

    9.5.1. MARKET TRENDS AND GROWTH FACTORS

    9.5.2. UNMET NEEDS AND OPPORTUNITIES

    9.5.3. ITALY ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.6. SPAIN

    9.6.1. MARKET TRENDS AND GROWTH FACTORS

    9.6.2. UNMET NEEDS AND OPPORTUNITIES

    9.6.3. SPAIN ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.7. JAPAN

    9.7.1. MARKET TRENDS AND GROWTH FACTORS

    9.7.2. UNMET NEEDS AND OPPORTUNITIES

    9.7.3. JAPAN ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.8. CHINA

    9.8.1. MARKET TRENDS AND GROWTH FACTORS

    9.8.2. UNMET NEEDS AND OPPORTUNITIES

    9.8.3. CHINA ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.9. INDIA

    9.9.1. MARKET TRENDS AND GROWTH FACTORS

    9.9.2. UNMET NEEDS AND OPPORTUNITIES

    9.9.3. INDIA ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.10. BRAZIL

    9.10.1. MARKET TRENDS AND GROWTH FACTORS

    9.10.2. UNMET NEEDS AND OPPORTUNITIES

    9.10.3. BRAZIL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.11. RUSSIA

    9.11.1. MARKET TRENDS AND GROWTH FACTORS

    9.11.2. UNMET NEEDS AND OPPORTUNITIES

    9.11.3. RUSSIA ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)

    9.12. ROW

    9.12.1. MARKET TRENDS AND GROWTH FACTORS

    9.12.2. UNMET NEEDS AND OPPORTUNITIES

    9.12.3. ROW MARKET SIZE (2018), FORECAST (2019-2025)

    10. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

    10.1. COMPANIES

    10.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS

    10.1.2. TOP 20 EMERGING COMPANIES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

    10.2. UNIVERSITIES AND INSTITUTES

    11. ABBREVIATIONS

List Of Tables
in Activated PI3K Delta Syndrome (APDS) Therapeutic Market: Opportunities Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)

LIST OF TABLES

TABLE 1: REPORT HIGHLIGHTS IN NUMERICALS

TABLE 2: LIST OF FDA APPROVED DRUGS FOR ACTIVATED PI3K DELTA SYNDROME (APDS)

TABLE 3: LIST OF EMA APPROVED DRUGS FOR ACTIVATED PI3K DELTA SYNDROME (APDS)

TABLE 4: ACTIVATED PI3K DELTA SYNDROME (APDS) EPIDEMIOLOGY (2018), FORECAST (2019-2025)

TABLE 5: MAJOR ACQUISITIONS AND MERGERS IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

TABLE 6: MAJOR COLLABORATIVE AGREEMENTS IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

TABLE 7: MAJOR LICENSING AGREEMENTS IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

TABLE 8: MAJOR PARTNERSHIPS AND JOINT VENTURE IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

TABLE 9: MAJOR GRANTS AND FUNDINGS IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

TABLE 10: MAJOR ALLIANCE DEALS IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

TABLE 11: US FDA APPROVED DRUGS FOR ACTIVATED PI3K DELTA SYNDROME (APDS) SINCE 2010

TABLE 12: EX-US APPROVED DRUGS FOR ACTIVATED PI3K DELTA SYNDROME (APDS) SINCE 2010

TABLE 13: PRE-REGISTRATION (FILED) MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE

TABLE 14: PHASE 3 MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE

TABLE 15: PHASE 2 MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE

TABLE 16: PHASE 1 MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE

TABLE 17: PRECLINICAL MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE

TABLE 18: EARLY R&D MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE

TABLE 19: TERMINATED AND INACTIVE MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE

TABLE 20: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION

TABLE 21: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE MOLECULES OVERVIEW BY DRUG CLASS

TABLE 22: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE MOLECULES BY UNIVERSITIES

TABLE 23: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE MOLECULES BY INSTITUTES

TABLE 24: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES

TABLE 25: KEY PHASE 3 ONGOING CLINICAL TRIALS

TABLE 26: KEY PHASE 2 ONGOING CLINICAL TRIALS

TABLE 27: KEY PHASE 1 ONGOING CLINICAL TRIALS

TABLE 28: PLANNED CLINICAL TRIALS FOR THE ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

TABLE 29: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS

TABLE 30: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS

TABLE 31: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS

TABLE 32: GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY DRUG CLASS (2019-2025)

TABLE 33: GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY ROA (2019-2025)

TABLE 34: STRENGTH, DOSAGE AND ROA OF ACTIVATED PI3K DELTA SYNDROME (APDS) DRUGS

TABLE 35: TOP TEN COUNTRIES/TERRITORIES FOR NUMBER OF NEW CASES OF ACTIVATED PI3K DELTA SYNDROME (APDS) PER YEAR

TABLE 36: GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY GEOGRAPHY, MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 37: US MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 38: UK MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 39: GERMANY MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 40: FRANCE MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 41: ITALY MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 42: SPAIN MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 43: JAPAN MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 44: CHINA MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 45: INDIA MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 46: BRAZIL MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 47: RUSSIA MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 48: ROW MARKET SIZE (2018), FORECAST (2019-2025)

TABLE 49: LIST OF ESTABLISHED COMPANIES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

TABLE 50: LIST OF EMERGING COMPANIES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

TABLE 51: COMPETITIVE OPPORTUNITIES, UNIVERSITIES

TABLE 52: COMPETITIVE OPPORTUNITIES, INSTITUTES

(ABOVE MENTIONED TABLES ARE A FEW AMONG THE TOTAL 102 TABLES IN THE REPORT)

List Of Figures, Charts and Diagrams
in Activated PI3K Delta Syndrome (APDS) Therapeutic Market: Opportunities Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)

LIST OF FIGURES:

FIGURE 1: GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET 2019-2025: MARKET SNAPSHOT

FIGURE 2: GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY GEOGRAPHY 2018 V/S 2025

FIGURE 3: ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY ROA, 2018

FIGURE 4: ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY AGE GROUP, 2018

FIGURE 5: KEY INFLECTION POINTS IN ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET (2015-2030)

FIGURE 6: ACTIVATED PI3K DELTA SYNDROME (APDS) MAJOR FINDINGS

FIGURE 7: MEDICAL EXPENDITURES FOR ACTIVATED PI3K DELTA SYNDROME (APDS)

FIGURE 8: ACTIVATED PI3K DELTA SYNDROME (APDS) EPIDEMIOLOGY (2018), FORECAST (2019-2025)

FIGURE 9: OVERALL DEALS ACTIVITY IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA

FIGURE 10: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE

FIGURE 11: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT

FIGURE 12: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE ANALYSIS BY GEOGRAPHY

FIGURE 13: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES

FIGURE 14: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 15: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE ANALYSIS BY DRUG CLASS

FIGURE 16: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD

FIGURE 17: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD

FIGURE 18: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES

FIGURE 19: GRAPHICAL REPRESENTATION OF GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY DRUG CLASS

FIGURE 20: GRAPHICAL REPRESENTATION OF GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY ROA

FIGURE 21: GRAPHICAL REPRESENTATION, US MARKET SIZE 2018 V/S 2025

FIGURE 22: GRAPHICAL REPRESENTATION, UK MARKET SIZE 2018 V/S 2025

FIGURE 23: GRAPHICAL REPRESENTATION, GERMANY MARKET SIZE 2018 V/S 2025

FIGURE 24: GRAPHICAL REPRESENTATION, FRANCE MARKET SIZE 2018 V/S 2025

FIGURE 25: GRAPHICAL REPRESENTATION, ITALY MARKET SIZE 2018 V/S 2025

FIGURE 26: GRAPHICAL REPRESENTATION, SPAIN MARKET SIZE 2018 V/S 2025

FIGURE 27: GRAPHICAL REPRESENTATION, JAPAN MARKET SIZE 2018 V/S 2025

FIGURE 28: GRAPHICAL REPRESENTATION, CHINA MARKET SIZE 2018 V/S 2025

FIGURE 29: GRAPHICAL REPRESENTATION, INDIA MARKET SIZE 2018 V/S 2025

FIGURE 30: GRAPHICAL REPRESENTATION, BRAZIL MARKET SIZE 2018 V/S 2025

FIGURE 31: GRAPHICAL REPRESENTATION, RUSSIA MARKET SIZE 2018 V/S 2025

FIGURE 32: GRAPHICAL REPRESENTATION, ROW MARKET SIZE 2018 V/S 2025

FIGURE 33: COMPANY FINANCIAL INFORMATION

FIGURE 34: COMPANY SWOT ANALYSIS

(ABOVE MENTIONED FIGURES ARE A FEW AMONG THE TOTAL 51 FIGURES IN THE REPORT)

Additional Details

Publisher

Gervano R A

Publisher Information

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.



GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.



At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Reference

270535 | GERPHME171

Number of Pages

215

Report Format

PDF

Gervano R A Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Activated Carbon Market by Type (Powdered, Granular, Others (Pelletized, Bead)), Application (Liquid Phase (Water Treatment, Foods & Beverages, Pharmaceutical & Medical), Gaseous Phase (Industrial, Automotive)), Region - Global Forecast to 2021
“Stringent government regulations for emission control, mercury control from power plants, high dema...
23 Jan 2017 by MarketsandMarkets USD $5,650 More Info
2017-2021 APTT (Activated Partial Thromboplastin Time) Market: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
The growing cost-containment pressures in major industrialized nations and continued technological a...
19 Jan 2017 by Venture Planning Group (VPG) USD $3,850 More Info
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2016
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein ...
28 Dec 2016 by Global Markets Direct USD $3,500 More Info
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Pipeline Review, H2 2016
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal R...
30 Nov 2016 by Global Markets Direct USD $3,500 More Info
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Pipeline Review, H2 2016
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated...
30 Nov 2016 by Global Markets Direct USD $3,500 More Info
APTT (Activated Partial Thromboplastin Time): US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
The growing cost-containment pressures in major industrialized nations and continued technological a...
27 Jun 2016 by Venture Planning Group (VPG) USD $3,850 More Info
APTT (Activated Partial Thromboplastin Time): US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
The growing cost-containment pressures in major industrialized nations and continued technological a...
27 Jun 2016 by Venture Planning Group (VPG) USD $3,850 More Info
Air Purification Systems Market Product (Dust Collectors, Fume & Smoke Collectors, Vehicle Exhaust, Others), Technology (HEPA, ESP, Activated Carbon, Ionic Filters, Others), End-Use Sector (Automotive, Construction, Healthcare, Others) - Forecast to 2020
“Increasing level of air pollution in the atmosphere, rapid industrialization, and increasing urbani...
07 Dec 2015 by MarketsandMarkets USD $5,650 More Info
Adsorbents Market by Type (Molecular Sieves, Activated Carbon and Alumina, Silica Gel,Clay, and Others), by Application (Petrochemicals, Water Treatment, Air Separation & Drying, and Others), and by Region - Global Trends and Forecast to 2020
North America is the leader in the global adsorbents market and accounts for the largest market size...
04 Dec 2015 by MarketsandMarkets USD $5,650 More Info
Air Filters Market by Type (Intake & Cabin), Filter Media (Intake-Cellulose & Synthetic, Cabin-Particle & Activated Carbon), Vehicle Type (Passenger Car, LCV, HCV, & Off- Highway), Market (OE & Aftermarket), & by Region - Global Forecast to 2020
The function of the intake air filter is to restrict the entry of airborne contaminants in the engin...
17 Aug 2015 by MarketsandMarkets USD $5,650 More Info

This report is published by Gervano R A

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Download Free Report Summary PDF

Activated PI3K Delta Syndrome (APDS) Therapeutic Market: Opportunities Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028) | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...